Skip to content
Precision for Medicine
Breaking News

Precision Wins Fierce CRO Award for Innovative Solutions in Drug Development

false
Fred, Snikeris Avatar

Fred Snikeris

Fred Snikeris, PhD is an established biometrics executive with extensive Pharmaceutical R&D and CRO experience. He has built self-sustaining global multi-site biostatistics departments in support of late phase and early phase clinical development and preclinical research efforts.
  • Read: Phase I Clinical Trial Designs: Modified Toxicity Probability Interval Modified Toxicity Probability Interval

    Clinical Trials - Early Phase Research - Oncology

    Phase I Clinical Trial Designs: Modified Toxicity Probability Interval

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778869, hs_child_table_id=0, hs_updated_at=1715692377826, hs_published_at=1748379090824, description=Fred Snikeris, PhD is an established biometrics executive with extensive Pharmaceutical R&D and CRO experience. He has built self-sustaining global multi-site biostatistics departments in support of late phase and early phase clinical development and preclinical research efforts., avatar=Image{width=720,height=812,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Fred-Snikeris.png',altText='Fred-Snikeris',fileId=167370698299}, linkedin=https://www.linkedin.com/in/fredsnikeris, hs_name=, hs_path=, lastname=Snikeris, hs_initial_published_at=1716212769184, hs_created_at=1709645745100, hs_is_edited=false, hs_deleted_at=0, name=Fred, job=, slug=fred-snikeris, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Fred Snikeris avatar

      Fred Snikeris

    Discover
Loading...
You've reach the end